Skip to Accessibility Tools Skip to Content Skip to Footer

What is Tecentriq®(atezolizumab)?

Tecentriq® (atezolizumab) is a biologic immunotherapy medication that is approved by the Food and Drug Administration (FDA) as a first-line treatment for some women with advanced triple-negative breast cancer. The FDA granted accelerated approval for Tecentriq, which means that early data from a clinical study strongly suggests that patients benefitted from treatment with this medication.1

Tecentriq was approved to be used in combination with the chemotherapy medicine Abraxane (nab–paclitaxel). The combination is used for women with locally advanced or metastatic triple-negative breast cancer that cannot be treated surgically and whose tumors have a protein called PD-L1.

Locally advanced breast cancer is cancer that has spread beyond the breast, to the chest wall, skin, or lymph nodes, but it has not spread to other parts of the body.2 Metastatic breast cancer has spread to other parts of the body.

Triple-negative breast cancer refers to tumors that do not display a series of molecules that are common targets of chemotherapy. About 15-20% of breast cancers are triple-negative. Specifically, this type of breast cancer is3:

  • Estrogen receptor-negative
  • Progesterone receptor-negative
  • Human epidermal growth factor receptor 2 (HER2)-negative

What are the ingredients in Tecentriq?

The active ingredient in Tecentriq is atezolizumab.

How does Tecentriq work?

Tecentriq is one of several engineered monoclonal antibodies used to treat cancer. Our bodies naturally produce antibodies, which are immune factors that act against bacteria, viruses, and other foreign organisms that invade and pose a threat to our health. Drugmakers have engineered a variety of antibodies to target the mechanisms that cause certain diseases, including breast cancer. Tecentriq is designed to bind to a specific molecule, called PD-L1, that appears on the surface of some breast cancers. PD-L1 effectively hides the tumor from our body’s natural immune system. Tecentriq binds to PD-L1, which disrupts its tumor-shrouding action. This allows the body’s immune system to recognize and attack the tumor.4

Tecentriq works only with tumors that display the PD-L1 molecule. Before doctors prescribe this medicine, they will test your tumor to be sure it has PD-L1. Otherwise, the medication won’t work.

What are the possible side effects of Tecentriq?

Common side effects with Tecentriq include5:

  • Hair loss
  • Tingling or numbness in hands or feet
  • Tiredness
  • Nausea
  • Diarrhea
  • Low red blood cells (anemia)
  • Constipation
  • Cough
  • Headache
  • Low white blood cells
  • Vomiting
  • Decreased appetite

In some patients, Tecentriq may cause more harmful, sometimes life-threatening side effects. These include5:

  • Lung problems, called pneumonitis
  • Liver problems, called hepatitis
  • Intestinal problems, called colitis
  • Problems in your hormone-secreting glands, especially the pancreas, thyroid, adrenal glands, and pituitary
  • Problems in other parts of the body, including the eyes, heart, skin, and nervous system
  • Severe infections
  • Severe reaction to infusion, which is how the medication is given

Tecentriq has been shown to harm fetuses, so it is important not to become pregnant or breastfeed while you are taking it. This is not a complete list of all potential side effects of Tecentriq. For more information, consult your doctor or healthcare provider. If you notice any new or worsening side effects, contact your doctor or healthcare provider immediately.

Things to note about Tecentriq

Before taking Tecentriq, tell your doctor if you5:

  • Have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
  • Have had an organ transplant
  • Have lung or breathing problems
  • Have liver problems
  • Have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
  • Are pregnant or plan to become pregnant or are breastfeeding

Tell your doctor about any medications or supplements you are taking while on Tecentriq.

Dosing information

Tecentriq is given either through a vein in your arm via intravenous (IV) infusion. Infusions of Tecentriq must be given in a medical office, and they take about 30-60 minutes to complete. The infusion dose includes 840 mg of medicine. Treatments are given monthly, on days 1 and 15.4 Tecentriq was approved to be used in combination with a specific chemotherapy medicine, known by the generic name of paclitaxel. Paclitaxel is also given intravenously. In addition to your treatment with Tecentriq, you will receive paclitaxel on days 1, 8, and 15.4 For more information about Tecentriq, read the complete prescribing information.

Written by: Editorial Team | Last reviewed: July 2019.
  1. Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer. National Cancer Institute. March 28, 2019. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2019/atezolizumab-triple-negative-breast-cancer-fda-approval Accessed July 18, 2019.
  2. Locally Advanced or Inflammatory Breast Cancer. Susan G. Komen Breast Cancer Foundation. June 10, 2019. Available at: https://ww5.komen.org/BreastCancer/LocallyAdvancedInflammatoryBreastCancerStageIII.html Accessed July 12, 2019.
  3. Triple Negative Breast Cancer. Susan G. Komen Breast Cancer Foundation. May 27, 2019. Available at: https://ww5.komen.org/BreastCancer/TripleNegativeBreastCancer.html Accessed July 19, 2019.
  4. Prescribing Information. Genentech. 2019. Available at: https://www.gene.com/download/pdf/tecentriq_prescribing.pdf Accessed July 19, 2019.
  5. Tecentriq. DailyMed. US National Library of Medicine. May 13, 2019. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee Accessed July 19, 2019.